MedTrace Logo

Effect of Meloxicam Tablets on Bleeding Time in Healthy Subjects

NCT02183155 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 82

Last updated 2014-07-08

No results posted yet for this study

Summary

The primary purpose of this study was to evaluate the effect of meloxicam tablets (7.5, 15 mg and 30 mg) with meloxicam placebo. Extended-release indomethacin capsules (75 mg) was an active control to assess trial sensitivity on bleeding time in healthy subjects. The secondary aim of this study was to assess effects of treatment on other platelet function and coagulation parameters.

Conditions

  • Healthy

Interventions

DRUG

Meloxicam - low

DRUG

Meloxicam - medium

DRUG

Meloxicam - high

DRUG

Placebo

DRUG

Extended-release indomethacin

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2000-05-31
Primary Completion
2000-09-30

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02183155 on ClinicalTrials.gov